HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Tanuja Chitnis, MD

Associate neurologist, Brigham and Women's Hospital; professor of neurology, Harvard Medical School


Exploiting Anti-CD3 Antibodies, Relevant Biomarkers in Progressive MS: Tanuja Chitnis, MD

June 24, 2022

The associate neurologist at Brigham and Women’s Hospital provided insight on the current state of promising targets in progressive MS and why anti-CD3 therapy might be a new consideration for future trials. [WATCH TIME: 2 minutes]

The Potential of Targeting Anti-CD3 in Progressive Multiple Sclerosis: Tanuja Chitnis, MD

June 22, 2022

The associate neurologist at Brigham and Women’s Hospital provided background on a new case study of a patient with progressive MS who showed positive outcomes using foralumab, an anti-CD3 targeting agent. [WATCH TIME: 3 minutes]

Defining Treatment Failure in Pediatric MS

April 27, 2021

Lauren B. Krupp, MD considers how treatment failure in pediatric multiple sclerosis may be defined as disease relapse, new or enlarging legions, inability to tolerate treatment, or lack of adherence.

Disease-Modifying Therapy in Relapsing-Remitting MS

April 20, 2021

Leaders in neurology provide insight into first-line disease-modifying therapies for relapsing-remitting multiple sclerosis, such as interferon or glatiramer acetate, and glucocorticoids for acute events.

Treatment Goals and Response Monitoring in Pediatric MS

April 13, 2021

Tanuja Chitnis, MD reviews the 2018 AAN guidelines on disease-modifying therapies and discusses goals of therapy when selecting first-line treatments and monitoring response in pediatric multiple sclerosis.

Emotional, Social, and Cognitive Challenges in Pediatric MS

April 13, 2021

Experts in multiple sclerosis discuss the importance of a multidisciplinary approach for pediatric patients and emphasize the role of social workers, psychologists, and support groups for patients and families.